From a multiple-dose vial (MDV), bill only the amount actually administered, converted to billing units at the HCPCS descriptor and rounded up to the next whole unit — never round down, and never bill for what stayed in the vial. JW and JZ do not belong on that line at all, in any amount: both modifiers exist only for single-dose or single-use containers, by FDA labeling, and CMS says so directly — “the use of these modifiers is not appropriate for drugs that are from multiple-dose containers” (Pub. 100-04, Ch. 17, §40). A J2560 phenobarbital dose of 90 mg against the “up to 120 mg” descriptor is 1 unit; 130 mg is 2 units — but CMS’s own JW/JZ code list carries no multiple-dose phenobarbital product, so check the label on the vial actually drawn before assuming this question is even about an MDV.
One label word settles every question on this page: does the vial say “Single-Dose,” “Single-Use,” or “SDV” on the FDA-approved labeling, or does it say “Multi-Dose” or “MDV”? CMS states the scope of the waste modifiers directly:
“In general, the JW and JZ modifier policy applies to all drugs separately payable under Medicare Part B that are described as being supplied in a ‘single-dose’ container or ‘single-use’ package based on FDA-approved labeling… However, the use of these modifiers is not appropriate for drugs that are from multiple-dose containers.” — Source §40 (Pub. 100-04, Ch. 17)
Nothing there turns on vial size or what a similar drug does. CMS’s running list of the specific HCPCS codes its JW/JZ policy reaches states the exclusion in its own header: “codes with 1 or more multiple-dose containers assigned to it are excluded from the list.” A code with a genuine MDV presentation on the market is not on it, whatever else that code also covers.
Once a drug is confirmed as an MDV, the billing-unit math is a straight conversion at the HCPCS long descriptor, with one rounding rule attached:
“Drugs are billed in multiples of the dosage specified in the HCPCS code long descriptor. If the drug dose used in the care of a patient is not a multiple of the HCPCS code dosage descriptor, the provider rounds to the next highest unit based on the HCPCS long descriptor for the code in order to report the dose provided.” — Source §10 (Pub. 100-04, Ch. 17)
J1100 (dexamethasone sodium phosphate) reports 1 mg per unit, so a 10 mg dose drawn from a 30 mL, 10 mg/mL multiple-dose vial is exactly 10 units — the dose lands on the descriptor, nothing to round. J3420 (cyanocobalamin, “up to 1,000 mcg” per unit) treats 1 mL of a 1,000 mcg/mL MDV as one full unit; a smaller draw would still round up to 1 unit, because the descriptor’s ceiling, not a linear per-mcg rate, is what a fraction rounds against. Depo-Medrol (methylprednisolone acetate) bills a single descriptor, J1010, at 1 mg per unit — CMS retired J1020, J1030 and J1040 effective March 31, 2024, and J1010 took over April 1, 2024. A 40 mg dose from a 5 mL, 40 mg/mL vial is J1010 × 40; an 80 mg dose from the same size vial is J1010 × 80; a 120 mg dose is J1010 × 120 — every dose lands exactly on the 1 mg descriptor, so there is nothing to round and no code-combination question. Depo-Medrol ships in both container types, and the vial in hand decides JW/JZ, not the drug name: the 1 mL, 40 mg/mL and 1 mL, 80 mg/mL vials are labeled single-dose, so JW/JZ applies in full when one of those is drawn from; the 5 mL and 10 mL vials — the ones behind the 40 mg and 80 mg doses above — are labeled multiple-dose, so neither modifier applies to a dose drawn from them, no matter how much stays in the vial. J1010’s MUE is 160 units, practitioner and facility, MAI 3 — well above any single Depo-Medrol dose.
J2560 reads “Injection, phenobarbital sodium, up to 120 mg” — an “up to” ceiling, not a per-mg rate, which is exactly why 90 mg and 130 mg land on different sides of a unit boundary:
The practitioner MUE for J2560 is 1 (MAI 3, “Clinical: Data”); the facility MUE is 16. A 130 mg dose at 2 units exceeds the practitioner ceiling outright and needs the chart — dose, indication, why 130 mg rather than 120 — attached to an appeal, not a resubmission with a modifier; MAI 3 edits are not modifier-bypassable. Before any of that: CMS’s own JW/JZ HCPCS code list carries J2560 with no multiple-dose container on file, so the “from a multi-dose vial” premise behind this exact search may not describe the vial in front of you. If the vial on the shelf is labeled single-dose, JW/JZ apply in full and every mg not administered is a JW line; if it is genuinely labeled multi-dose, the JW/JZ question does not arise and the units above stand alone. Read the label on the vial actually drawn, every time — not the assumption behind the search.
J0897 (denosumab, Prolia) is on CMS’s JW/JZ list with no multiple-dose exclusion, and its labeled dose is a single 60 mg/mL prefilled syringe:
The two rules never blend on one claim line — a code is either drawn from a single-dose container this encounter and gets JW or JZ, or it is drawn from a multiple-dose vial and gets neither, ever.
There is no waste line for an MDV, at any dose, on any date of service. The portion left in a multiple-dose vial when it is finally discarded — expired, contaminated, or simply no longer needed — is not a billable waste unit under any modifier; it is a cost of doing business, the same as an unused portion of a bottle of tablets. Billing JW or JZ against a container labeled “Multi-Dose” is a denial trigger in its own right, not a harmless extra modifier. A related but separate question is how long an opened MDV stays usable at all: the label on the specific product, not this billing rule, sets that window, and it is shorter than the vial’s unopened shelf life once punctured — a beyond-use-dating question, not a billing-units one, but the reason a vial that sat open too long gets discarded rather than drawn from for the next patient.
The MUE still applies per date of service, exactly as on a single-dose line — the MDV rule changes what is billable, not whether a unit ceiling exists. A J2560 dose at 2 units against a practitioner MUE of 1 fails the edit regardless of vial type. Run the dose through the units calculator before the claim goes out — it applies the round-up rule and flags an MUE breach — and the billing units reference has the descriptor-to-unit math for every code on this page.
Only if the vial you drew from is labeled single-dose. Confirm the FDA label first: CMS’s own JW/JZ code list carries J2560 with no multiple-dose exclusion on file, meaning most marketed phenobarbital sodium single-dose vials do generate a JW line for what is left after a 90 mg dose against the 120 mg descriptor. If the specific vial is genuinely labeled multi-dose, neither JW nor JZ applies and the discarded portion is not billable at all.
Because CMS’s rounding rule (Pub. 100-04, Ch. 17, §10) rounds any dose that is not an exact multiple of the descriptor up to the next whole unit, not up by the fraction actually used. 130 mg against a 120 mg-per-unit descriptor is 2 units on the administered line, and at 2 units it exceeds J2560’s practitioner MUE of 1 — expect that line to need supporting documentation.
No. Pub. 100-04, Ch. 17, §40 states plainly that the JW/JZ modifier policy is not appropriate for drugs from multiple-dose containers, regardless of how much is discarded when the vial is finally retired. Bill the administered amount, rounded up to the next whole unit, and stop there.
No. CMS deleted J1020, J1030 and J1040 effective March 31, 2024; J1010, at 1 mg per unit, took over April 1, 2024. Convert the dose directly — 40 mg is J1010 × 40, 80 mg is J1010 × 80, 120 mg is J1010 × 120 — and check the vial: the 1 mL single-dose vials take JW/JZ, the 5 mL and 10 mL multiple-dose vials take neither.
Quoted passages are reproduced from the cited federal publications; everything else is our reading of them. The methodology by which we resolve source disagreements is described in the Methodology.